New Highly Selective BACE1 Inhibitors and Their Effects on Dendritic Spine Density In Vivo

β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) is considered a therapeutic target to combat Alzheimer’s disease by reducing β-amyloid in the brain. To date, all clinical trials involving the inhibition of BACE1 have been discontinued due to a lack of efficacy or undesirable side effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Pratsch, Katrin, Unemura, Chie, Ito, Mana, Lichtenthaler, Stefan F., Horiguchi, Naotaka, Herms, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418759/
https://www.ncbi.nlm.nih.gov/pubmed/37569661
http://dx.doi.org/10.3390/ijms241512283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418759/
https://www.ncbi.nlm.nih.gov/pubmed/37569661
http://dx.doi.org/10.3390/ijms241512283

Ejemplares similares